截至9月30日，苑东生物股东户数6482.00，较上期增加18.67%；人均流通股27234股，较上期减少 15.74%。2025年1月-9月，苑东生物实现营业收入10.19亿元，同比减少2.00%；归母净利润2.20亿元，同 比增长1.45%。 分红方面，苑东生物A股上市后累计派现3.41亿元。近三年，累计派现2.12亿元。 12月29日，苑东生物盘中下跌2.09%，截至11:18，报58.70元/股，成交7644.89万元，换手率0.73%，总 市值103.62亿元。 资金流向方面，主力资金净流出276.58万元，特大单买入895.77万元，占比11.72%，卖出713.87万元， 占比9.34%；大单买入654.26万元，占比8.56%，卖出1112.73万元，占比14.56%。 苑东生物今年以来股价涨97.60%，近5个交易日涨0.24%，近20日涨9.66%，近60日涨7.02%。 资料显示，成都苑东生物制药股份有限公司位于四川省成都市双流区安康路8号，成立日期2009年6月1 日，上市日期2020年9月2日，公司主营业务涉及化学原料药和化学药制剂的研发、生产与销售。主营业 务收入构成为：制剂销售7 ...

12月29日，百利天恒盘中下跌2.04%，截至09:49，报331.66元/股，成交4767.21万元，换手率0.14%，总 市值1369.34亿元。 百利天恒所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌治癌、创新药、抗 癌药物、生物医药、中药等。 截至9月30日，百利天恒股东户数5979.00，较上期增加25.08%；人均流通股17208股，较上期减少 20.05%。2025年1月-9月，百利天恒实现营业收入20.66亿元，同比减少63.52%；归母净利润-4.95亿元， 同比减少112.16%。 机构持仓方面，截止2025年9月30日，百利天恒十大流通股东中，中欧医疗健康混合A（003095）位居 第三大流通股东，持股370.19万股，相比上期减少57.78万股。香港中央结算有限公司位居第四大流通股 东，持股289.57万股，相比上期减少69.64万股。华夏上证科创板50成份ETF（588000）位居第五大流通 股东，持股283.37万股，相比上期减少159.13万股。易方达上证科创板50ETF（588080）位居第六大流 通股东，持股229.92万股，相比上期减少101.89万股 ...

Core Viewpoint - The stock price of Weixin Kang has experienced fluctuations, with a recent decline of 2.00% and a year-to-date increase of 11.79% [1][2]. Group 1: Stock Performance - As of December 26, Weixin Kang's stock price is reported at 10.76 yuan per share, with a market capitalization of 4.682 billion yuan [1]. - The stock has seen a decline of 2.00% over the last five trading days, 4.78% over the last 20 days, and 7.03% over the last 60 days [2]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on July 8, where it recorded a net purchase of 759.81 million yuan [2]. Group 2: Financial Performance - For the period from January to September 2025, Weixin Kang reported a revenue of 862 million yuan, a year-on-year decrease of 13.27%, and a net profit attributable to shareholders of 219 million yuan, down 9.90% year-on-year [2]. - The company has distributed a total of 624 million yuan in dividends since its A-share listing, with 438 million yuan distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Weixin Kang is 16,500, reflecting a 14.14% increase from the previous period, while the average circulating shares per person decreased by 12.39% to 26,333 shares [2]. - Notably, several institutional investors have exited the top ten circulating shareholders list, including Guangfa Medical Healthcare Stock A and Xinao Small Cap Mixed A [3].

截至9月30日，百利天恒股东户数5979.00，较上期增加25.08%；人均流通股17208股，较上期减少 20.05%。2025年1月-9月，百利天恒实现营业收入20.66亿元，同比减少63.52%；归母净利润-4.95亿元， 同比减少112.16%。 机构持仓方面，截止2025年9月30日，百利天恒十大流通股东中，中欧医疗健康混合A（003095）位居 第三大流通股东，持股370.19万股，相比上期减少57.78万股。香港中央结算有限公司位居第四大流通股 东，持股289.57万股，相比上期减少69.64万股。华夏上证科创板50成份ETF（588000）位居第五大流通 股东，持股283.37万股，相比上期减少159.13万股。易方达上证科创板50ETF（588080）位居第六大流 通股东，持股229.92万股，相比上期减少101.89万股。永赢医药创新智选混合发起A（015915）位居第 七大流通股东，持股164.98万股，为新进股东。汇添富创新医药混合A（006113）位居第八大流通股 东，持股151.43万股，相比上期减少18.57万股。华泰柏瑞沪深300ETF（510300）位居第十大流通股 东，持股 ...

今年以来科伦药业已经2次登上龙虎榜，最近一次登上龙虎榜为4月30日，当日龙虎榜净买入3187.92万 元；买入总计2.54亿元 ，占总成交额比17.58%；卖出总计2.22亿元 ，占总成交额比15.37%。 资料显示，四川科伦药业股份有限公司位于四川省成都市青羊区百花西路36号，成立日期2002年5月29 日，上市日期2010年6月3日，公司主营业务涉及开发、生产和销售大输液产品。主营业务收入构成为： 非输液48.37%，输液41.28%，研发项目7.01%，其他3.33%。 科伦药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：幽门螺杆概念、熊去氧 胆酸、抗流感、原料药、医药电商等。 截至9月30日，科伦药业股东户数3.71万，较上期增加8.35%；人均流通股35200股，较上期减少7.70%。 2025年1月-9月，科伦药业实现营业收入132.77亿元，同比减少20.92%；归母净利润12.01亿元，同比减 少51.41%。 12月26日，科伦药业盘中下跌2.00%，截至10:44，报29.87元/股，成交2.63亿元，换手率0.67%，总市值 477.34亿元。 资金流向方面，主力资金 ...

12月26日，益方生物盘中下跌2.08%，截至09:54，报28.67元/股，成交4961.13万元，换手率0.41%，总 市值165.81亿元。 资金流向方面，主力资金净流出517.65万元，特大单买入129.21万元，占比2.60%，卖出128.15万元，占 比2.58%；大单买入481.09万元，占比9.70%，卖出999.80万元，占比20.15%。 截至9月30日，益方生物股东户数1.24万，较上期增加26.17%；人均流通股33810股，较上期减少 17.52%。2025年1月-9月，益方生物实现营业收入3089.35万元，同比增长61.27%；归母净利润-1.81亿 元，同比增长40.59%。 机构持仓方面，截止2025年9月30日，益方生物十大流通股东中，香港中央结算有限公司位居第一大流 通股东，持股1621.61万股，相比上期增加816.20万股。汇添富创新医药混合A（006113）位居第三大流 通股东，持股1031.11万股，相比上期增加34.92万股。中欧医疗健康混合A（003095）位居第六大流通 股东，持股814.77万股，相比上期减少94.47万股。永赢医药创新智选混合发起A（01 ...

Group 1 - The core viewpoint of the news is that Shutaishen's stock has shown significant volatility, with a year-to-date increase of 275.17% and recent fluctuations in trading volume and price [1][2] - As of December 25, Shutaishen's stock price was 27.80 yuan per share, with a total market capitalization of 13.282 billion yuan [1] - The company has experienced a net outflow of main funds amounting to 23.4642 million yuan, with large orders showing a buy-sell imbalance [1] Group 2 - Shutaishen's main business involves the research, production, and sales of biological products and some chemical drugs, with the primary revenue sources being the injection of mouse nerve growth factor (59.17%) and compound polyethylene glycol electrolyte powder (33.19%) [1] - As of September 30, the company reported a revenue of 181 million yuan for the first nine months of 2025, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.6895 million yuan, a decrease of 227.71% [2] - The company has not distributed any dividends in the last three years, with a total payout of 771 million yuan since its A-share listing [3]

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 108.85%, but a recent decline over the past 20 and 60 days, indicating potential concerns about future performance [1][2]. Financial Performance - For the period from January to September 2025, Yipinhong reported a revenue of 814 million yuan, a year-on-year decrease of 34.35%, while the net profit attributable to shareholders was -136 million yuan, an increase of 44.80% compared to the previous year [2]. - The company has distributed a total of 335 million yuan in dividends since its A-share listing, with 151 million yuan distributed over the last three years [3]. Stock Market Activity - As of December 25, Yipinhong's stock price was 35.63 yuan per share, with a trading volume of 150 million yuan and a market capitalization of 16.094 billion yuan [1]. - The stock has experienced a net outflow of 2.2549 million yuan from major funds, with significant buying and selling activity noted in large orders [1]. Shareholder Information - As of November 30, Yipinhong had 20,400 shareholders, a decrease of 1.73% from the previous period, with an average of 20,511 circulating shares per shareholder, an increase of 1.76% [2]. - New institutional shareholders include Hong Kong Central Clearing Limited and several mutual funds, indicating a shift in the shareholder base [3]. Business Overview - Yipinhong is primarily engaged in the research, production, and sales of its own pharmaceuticals, with a revenue composition of 61.12% from pediatric drugs, 22.71% from chronic disease medications, and 16.17% from other products [1]. - The company operates within the pharmaceutical and biotechnology sector, focusing on chemical pharmaceuticals and various therapeutic areas including hypertension and hepatitis [2].

机构持仓方面，截止2025年9月30日，诺诚健华十大流通股东中，富国精准医疗灵活配置混合A （005176）位居第六大流通股东，持股1215.49万股，相比上期减少42.71万股。万家优选（161903）位 居第七大流通股东，持股1000.00万股，为新进股东。平安医疗健康混合A（003032）位居第八大流通股 东，持股862.66万股，为新进股东。工银前沿医疗股票A（001717）位居第九大流通股东，持股800.00 万股，为新进股东。汇添富创新医药混合A（006113）位居第十大流通股东，持股686.03万股，相比上 期减少74.34万股。中欧医疗健康混合A（003095）、鹏华医药科技股票A（001230）、易方达医疗保健 行业混合A（110023）退出十大流通股东之列。 诺诚健华今年以来股价涨74.35%，近5个交易日跌2.68%，近20日跌17.30%，近60日跌23.75%。 责任编辑：小浪快报 12月25日，诺诚健华盘中下跌2.01%，截至10:06，报21.41元/股，成交5115.47万元，换手率0.88%，总 市值377.81亿元。 诺诚健华所属申万行业为：医药生物-化学制药-化学制剂。所 ...

12月24日，百利天恒盘中下跌2.00%，截至14:14，报342.40元/股，成交1.57亿元，换手率0.44%，总市 值1413.68亿元。 截至9月30日，百利天恒股东户数5979.00，较上期增加25.08%；人均流通股17208股，较上期减少 20.05%。2025年1月-9月，百利天恒实现营业收入20.66亿元，同比减少63.52%；归母净利润-4.95亿元， 同比减少112.16%。 机构持仓方面，截止2025年9月30日，百利天恒十大流通股东中，中欧医疗健康混合A（003095）位居 第三大流通股东，持股370.19万股，相比上期减少57.78万股。香港中央结算有限公司位居第四大流通股 东，持股289.57万股，相比上期减少69.64万股。华夏上证科创板50成份ETF（588000）位居第五大流通 股东，持股283.37万股，相比上期减少159.13万股。易方达上证科创板50ETF（588080）位居第六大流 通股东，持股229.92万股，相比上期减少101.89万股。永赢医药创新智选混合发起A（015915）位居第 七大流通股东，持股164.98万股，为新进股东。汇添富创新医药混合A（006 ...